Court Will Not Review DEA Determination That Doctor Cannot Prescribe Psilocybin Under Right To Try Act

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Court Will Not Review DEA Determination That Doctor Cannot Prescribe Psilocybin Under Right To Try Act

Dennis Tosh

February 1, 2022 at 14:37:17 ET

A federal appeals court has rejected a challenge to a DEA determination that psilocybin, a Schedule I drug, was not available to treat terminally ill cancer patients under the Right to Try Act (RTT Act), ruling that the court did not have jurisdiction to review the agency’s action (Advanced Integrative Medical Science Institute, P.L.L.C. v. Garland, 24 F.4th 1249 (9th Cir. 2022)). ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

Court Will Not Review DEA Determination That Doctor Cannot Prescribe Psilocybin Under Right To Try Act

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT